Abdera launched in early 2021 backed by 8 million Canadian dollars in seed financing from adMare BioInnovations and AbCellera Biologics, a Vancouver-based antibody developer.

Abdera plans to ask regulators to greenlight a phase 1 trial with the DLL3-targeting therapy sometime in 2024. There are four additional targets that Abdera has declared but remain undisclosed.

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD-147, a treatment aimed at neuroendocrine carcinoma. The biologic therapy is ...

Abdera’s lead program, ABD-147, is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225 Ac) to solid tumors expressing delta-like ligand 3 (DLL3 ...

Abdera’s R adio O ptimized V ector E nginee r ing (ROVEr™) platform enables the company to engineer potential best-in-class therapies for both clinically validated and novel targets that ...

SOUTH SAN FRANCISCO, Calif., April 23, 2025--Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and ...

Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer. A lead program with preclinical proof-of-concept data in small ...

SOUTH SAN FRANCISCO, Calif., January 09, 2025--Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and ...

Abdera Therapeutics, a radiopharmaceutical start-up, has raised $142 million in series A and B financing. The series A round was led by Versant Ventures and Amplitude Ventures; ...

Abdera Therapeutics Inc. emerged from stealth mode with $142 million in equity funding and plans to develop a pipeline of radiopharmaceutical drugs that will employ engineered heavy-chain-only ...